Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 655,700 shares, an increase of 42.0% from the May 15th total of 461,600 shares. Based on an average trading volume of 2,810,000 shares, the days-to-cover ratio is presently 0.2 days.
Separately, Dawson James lowered shares of Kintara Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, May 16th.
Several large investors have recently added to or reduced their stakes in KTRA. Geode Capital Management LLC increased its position in Kintara Therapeutics by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 292,064 shares of the company’s stock worth $251,000 after purchasing an additional 14,097 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of Kintara Therapeutics in the 3rd quarter valued at about $47,000. Renaissance Technologies LLC acquired a new position in shares of Kintara Therapeutics in the 4th quarter valued at about $104,000. Citadel Advisors LLC acquired a new position in shares of Kintara Therapeutics in the 4th quarter valued at about $127,000. Finally, Virtu Financial LLC lifted its position in Kintara Therapeutics by 371.4% during the 4th quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock worth $33,000 after acquiring an additional 51,144 shares in the last quarter. 10.37% of the stock is owned by institutional investors and hedge funds.
Kintara Therapeutics (NASDAQ:KTRA – Get Rating) last issued its quarterly earnings results on Friday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. As a group, equities analysts expect that Kintara Therapeutics will post -0.55 EPS for the current year.
About Kintara Therapeutics (Get Rating)
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
- Get a free copy of the StockNews.com research report on Kintara Therapeutics (KTRA)
- The Insiders Are Selling Chevron But You Shouldn’t
- Two Retailers The Analysts Are Buying
- Under-The-Radar RF Industries Is A Steal At These Prices
- Procter & Gamble Stock Continues to Be Resilient Despite Turmoil
- Insiders Sell Tractor Supply Company, Oh No!
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.